What is he best known for?
The fields of study he is best known for:
Apoptosis, Cancer research, Leukemia, Immunology and Cell biology are his primary areas of study.
His Apoptosis research is multidisciplinary, relying on both Cell, Signal transduction and Mitochondrion.
The study incorporates disciplines such as Cancer and Priming in addition to Mitochondrion.
His Cancer research study integrates concerns from other disciplines, such as Ex vivo, In vivo, Chemotherapy, MAPK/ERK pathway and Cancer cell.
The concepts of his Leukemia study are interwoven with issues in Myeloid and Lymphoma.
His Cell biology research is multidisciplinary, incorporating elements of Myeloid Cell Leukemia Sequence 1 Protein, Cell cycle, Activator and Molecular biology.
His most cited work include:
- An inhibitor of Bcl-2 family proteins induces regression of solid tumours (2807 citations)
- The landscape of somatic copy-number alteration across human cancers (2544 citations)
- Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. (1417 citations)
What are the main themes of his work throughout his whole career to date?
Anthony Letai mostly deals with Cancer research, Apoptosis, Cancer cell, Immunology and Cell biology.
The Cancer research study combines topics in areas such as Venetoclax, Leukemia, Chronic lymphocytic leukemia, Lymphoma and In vivo.
His research in Leukemia intersects with topics in Myeloid and Haematopoiesis.
His work deals with themes such as Cell, Priming, Cell culture and Mitochondrion, which intersect with Apoptosis.
His study in Cancer cell is interdisciplinary in nature, drawing from both Ex vivo, Breast cancer, Pharmacology and Bioinformatics.
His Cell biology research integrates issues from Bcl-2 family and Puma.
He most often published in these fields:
- Cancer research (48.06%)
- Apoptosis (38.71%)
- Cancer cell (22.90%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (48.06%)
- Venetoclax (19.68%)
- Apoptosis (38.71%)
In recent papers he was focusing on the following fields of study:
Anthony Letai mostly deals with Cancer research, Venetoclax, Apoptosis, Internal medicine and Oncology.
His Cancer research research includes themes of Chronic lymphocytic leukemia, Priming, Lymphoma, Breast cancer and Mitochondrion.
His biological study spans a wide range of topics, including Azacitidine, Myeloid leukemia, In vivo and Decitabine.
His work investigates the relationship between Apoptosis and topics such as Cell biology that intersect with problems in Enhancer.
Anthony Letai combines subjects such as Chemotherapy and Drug with his study of Oncology.
His Leukemia research incorporates themes from Myeloid and Transcription factor.
Between 2017 and 2021, his most popular works were:
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. (571 citations)
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study (291 citations)
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins (281 citations)
In his most recent research, the most cited papers focused on:
Anthony Letai focuses on Cancer research, Venetoclax, Apoptosis, Chronic lymphocytic leukemia and Myeloid.
The various areas that Anthony Letai examines in his Cancer research study include Transcription factor, Phosphorylation, Kinase, Mitochondrion and MCL1.
His Venetoclax research incorporates elements of Azacitidine, Vincristine, Decitabine and Lymphoma.
His work carried out in the field of Apoptosis brings together such families of science as Cell culture, Haematopoiesis, DNA damage, Cancer cell and Priming.
His Cancer cell research is multidisciplinary, incorporating perspectives in Cytotoxic T cell, Cell and Cell biology.
His research investigates the link between Myeloid and topics such as Myeloid leukemia that cross with problems in Leukemia, DNA methylation and DNA Methyltransferase Inhibitor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
